Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HOOKIPA PharmaHOOK 50 Debt-to-Equity is 0.02 as of Jun. 2025. GuruFocus rates HOOK with a GF Score™ of 50/100. Among 965 Biotechnology companies, HOOKIPA Pharma ranks better than 88.08% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for HOOKIPA Pharma's Debt-to-Equity or its related term are showing as below:
HOOK's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16 * Ranked among companies with meaningful Debt-to-Equity only.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
HOOKIPA Pharma Debt-to-Equity Related Terms
HOOKIPA Pharma Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for HOOKIPA Pharma's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOOK vs COCP, LNAI, CYCN: Debt-to-Equity Comparison
For the Biotechnology subindustry, HOOKIPA Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HOOKIPA Pharma Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where HOOKIPA Pharma's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOOKIPA Pharma (HOOK) has a Debt-to-Equity of 0.02 as of Jun. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on HOOKIPA Pharma and its competitors. According to the industry distribution chart, HOOKIPA Pharma ranks #115 out of 965 companies in the Biotechnology industry, placing it in the top 11.9%.
Is HOOKIPA Pharma's Debt-to-Equity too high?
HOOKIPA Pharma's current Debt-to-Equity is 0.02. The Biotechnology industry median Debt-to-Equity is 0.16. HOOKIPA Pharma's value of 0.02 is 87.5% below this industry median. Based on the distribution chart, HOOKIPA Pharma ranks #115 out of 965 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HOOKIPA Pharma has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's Debt-to-Equity compare to COCP and LNAI?
According to the Biotechnology industry distribution chart, HOOKIPA Pharma ranks #115 out of 965 companies for Debt-to-Equity. This places HOOKIPA Pharma in the top 12% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. HOOKIPA Pharma's value of 0.02 is 87.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HOOKIPA Pharma's current Debt-to-Equity of 0.02 is 87.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on HOOKIPA Pharma and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HOOKIPA Pharma's current Debt-to-Equity is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
HOOKIPA Pharma (HOOK) has a current Debt-to-Equity of 0.02. The current Debt-to-Equity is 0.02 and 87.5% below the Biotechnology industry median of 0.16. HOOKIPA Pharma's overall GF Score™ is 50/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current Debt-to-Equity is 0.02 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
50GF Score
Get the complete analysis for HOOK
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOOK has been successfully added to your 
